Immunovant Inc
Research Immunovant Inc (IMVT) on Bullrun: market cap USD 8.97B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMVT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.97B
- Financial periodFY2026
- Net income-USD 505.61M
- Free cash flow-USD 407.32M
Valuation Snapshot
latest market cap is USD 8.97B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -USD 505.61M | -USD 407.32M | n/a | -2.77 | USD 902.11M | USD 72.00K | USD 852.59M |
| FY2025 | USD 0 | -USD 413.84M | -USD 376.63M | n/a | -2.73 | USD 713.97M | USD 98.00K | USD 707.45M |
| FY2024 | USD 0 | -USD 259.34M | -USD 214.59M | n/a | -1.88 | USD 635.37M | USD 23.00K | USD 617.76M |
| FY2023 | n/a | -USD 210.96M | -USD 188.39M | n/a | -1.71 | USD 376.53M | USD 306.00K | USD 362.49M |
| FY2022 | n/a | -USD 156.73M | -USD 106.37M | n/a | -1.43 | USD 493.82M | USD 2.08M | USD 469.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.97B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.17B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.65B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.09B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.29B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 980.74M | n/a | n/a | n/a |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunovant Inc's market cap?
Immunovant Inc's market capitalization is USD 8.97B.
What does Immunovant Inc do?
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.